POINT Biopharma Confirms No Delays to SPLASH Trial Due to Recent Global Lutetium Supply Interruption
March 22, 2022 08:30 ET
|
POINT Biopharma
INDIANAPOLIS, March 22, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT Biopharma to Host Dosimetry Investor Education Event on March 29, 2022
March 15, 2022 16:30 ET
|
POINT Biopharma
Learn what “PNT2002 has a favorable and safe dosimetry profile in the patient population and dose regimen being studied” means in the context of radiopharmaceuticals Register online at...
POINT Biopharma Announces Abstract Publication of Dosimetry Data Findings from the Lead-In Cohort of the SPLASH trial in mCRPC at the 2022 SNMMI Mid-Winter & ACNM Annual Meeting
February 25, 2022 09:00 ET
|
POINT Biopharma
Dosimetry data demonstrated PNT2002 has a favorable and safe dosimetry profile in the patient population and dose regimen being studied Red marrow dosimetry was well below critical thresholds,...
POINT Biopharma to Participate in Upcoming Virtual Investor Conferences
February 17, 2022 08:30 ET
|
POINT Biopharma
INDIANAPOLIS, Feb. 17, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to...
POINT Biopharma Provides Early-Stage Program Updates
February 14, 2022 08:30 ET
|
POINT Biopharma
Phase 1 therapeutic trial for PNT6555, the lead of the pan-cancer PNT2004 fibroblast activation protein-alpha (FAP-alpha) inhibitor program, planned for summer 2022 Initiated IND-enabling studies for...
POINT Biopharma Provides Update on Manufacturing, Supply Chain and Late-Stage Programs
February 01, 2022 08:30 ET
|
POINT Biopharma
Company’s radiopharmaceutical manufacturing facility now operational, supplying doses for the Phase 3 SPLASH trial – view the facility at manufacturing.pointbiopharma.com Will receive actinium-225 in...
POINT Biopharma Adds Senior BD Expertise with Appointment of Dr. Matthew Vincent as SVP, Business Development
January 04, 2022 08:30 ET
|
POINT Biopharma
INDIANAPOLIS, Jan. 04, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life...
POINT Biopharma adds a COO, Further Strengthens Leadership Team, and Announces Additional Board and Leadership Changes
December 01, 2021 08:30 ET
|
POINT Biopharma
Justyna Kelly promoted to COO, Dr. Robin Hallett promoted to VP, Discovery and Translational Sciences, Dr. Sherin Al-Safadi to join as VP Medical Affairs, and Michael Gottlieb (CCO) to depart the...
POINT Biopharma Licenses Innovative Lu-177 Production Technology from SCK CEN (Belgian Nuclear Research Center)
November 24, 2021 08:30 ET
|
POINT Biopharma
INDIANAPOLIS and MOL, Belgium , Nov. 24, 2021 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life changing...
POINT Biopharma to Host Virtual Education Event on December 6, 2021
November 22, 2021 08:30 ET
|
POINT Biopharma
POINT to host inaugural educational event highlighting radiopharmaceuticals, their therapeutic benefit, and commercial considerations Register online at https://hub.pointbiopharma.com/dec2021 ...